PMID- 32492927
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 6
DP  - 2020 Jun 1
TI  - Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol 
      Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus.
LID - 10.3390/jcm9061675 [doi]
LID - 1675
AB  - Ezetimibe reduces cardiovascular risk by lowering the levels of low-density 
      lipoprotein cholesterol (LDL-C). However, there is limited information regarding 
      the factors associated with ezetimibe-mediated LDL-C reduction. We investigated 
      the factors associated with LDL-C reduction after ezetimibe administration in 
      Japanese patients with or without type 2 diabetes mellitus (T2DM). This 
      single-center retrospective observational study enrolled a total of 266 
      consecutive ezetimibe-naive patients, of which 154 were excluded because of 
      either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe 
      discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To 
      identify the factors influencing LDL-C levels, univariate and multivariate linear 
      regression analyses were performed after 52 weeks of ezetimibe treatment. 
      Overall, advanced age, T2DM, and high baseline LDL-C were significantly 
      associated with a greater decrease in LDL-C levels. In the non-T2DM group, 
      advanced age and high baseline LDL-C were associated with greater decrease in 
      LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that 
      influenced the change in LDL-C levels. Advanced age was significantly associated 
      with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. 
      Ezetimibe use might be beneficial in older patients without T2DM. The lack of 
      association between age and the LDL-C lowering effect by ezetimibe in patients 
      with T2DM may be due to yet unknown mechanism except low statistical power.
FAU - Yamaguchi, Satoshi
AU  - Yamaguchi S
AUID- ORCID: 0000-0002-2687-2830
AD  - Department of Diabetes, Endocrinology and Metabolism, School of Medicine, 
      Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.
AD  - Department of Cardiology, Nakagami Hospital, 610 Noborikawa, Okinawa 904-2195, 
      Japan.
FAU - Oba, Kageyuki
AU  - Oba K
AD  - Department of Cardiology, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 
      901-0243, Japan.
FAU - Higa, Moritake
AU  - Higa M
AD  - Department of Diabetes and Life-Style Related Disease Center, Tomishiro Central 
      Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan.
FAU - Arasaki, Osamu
AU  - Arasaki O
AD  - Department of Cardiology, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 
      901-0243, Japan.
FAU - Shimabukuro, Michio
AU  - Shimabukuro M
AUID- ORCID: 0000-0001-7835-7665
AD  - Department of Diabetes, Endocrinology and Metabolism, School of Medicine, 
      Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200601
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7356893
OTO - NOTNLM
OT  - age
OT  - ezetimibe
OT  - low-density lipoprotein cholesterol
COIS- The authors declared no conflict of interest.
EDAT- 2020/06/05 06:00
MHDA- 2020/06/05 06:01
PMCR- 2020/06/01
CRDT- 2020/06/05 06:00
PHST- 2020/05/03 00:00 [received]
PHST- 2020/05/28 00:00 [revised]
PHST- 2020/05/29 00:00 [accepted]
PHST- 2020/06/05 06:00 [entrez]
PHST- 2020/06/05 06:00 [pubmed]
PHST- 2020/06/05 06:01 [medline]
PHST- 2020/06/01 00:00 [pmc-release]
AID - jcm9061675 [pii]
AID - jcm-09-01675 [pii]
AID - 10.3390/jcm9061675 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jun 1;9(6):1675. doi: 10.3390/jcm9061675.